UNSPSC 51161521: Cilomilast

This classification denotes a phosphodiesterase inhibitor with the molecular formula C20H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8ATB1C1R6X, chemically known as cyclohexanecarboxylic acid, 4-cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl)-, cis- but generally known as cilomilast, which bears US NIH Compound Identifier 151170. European Medicines Agency schedules Cilomilast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01296MIG.

UNSPSC 51161521 Cilomilast (Commodity) encompasses pharmaceutical products sourced through state and local cooperative purchasing agreements that aggregate demand across multiple jurisdictions and authorized wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, actively solicits manufacturers and suppliers of generic multi-source pharmaceuticals and over-the-counter products for distribution to participating state and local government facilities. Work under this code involves providing pharmaceuticals with specified National Drug Codes (NDC), maintaining compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), establishing contractual relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and offering pricing flexibility through formats such as flat price, net price, or WAC-minus structures. Vendors must maintain comprehensive insurance coverage including commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and ensure products possess expiration dates of at least one year from manufacture with minimum six-month shelf life. The issuing body for the primary recent solicitation is a multistate cooperative purchasing entity serving state and local government facilities across multiple jurisdictions including Minnesota and Oregon.

MMCAP's February 2026 RFP for generic multi-source pharmaceuticals and OTC products (solicitation S1070000015802, due March 26, 2026) represents current activity in the code. The contract term extends two years for new responders with optional extensions at MMCAP's discretion, with incumbent responders' amendments aligning through June 30, 2028. Evaluation criteria weight price competitiveness at 75 percent, fixed pricing for the contract term at 10 percent, compliance with administrative requirements and EDI capability at 5 percent each, and agreement to a 3 percent administrative fee at 5 percent. All awarded vendors must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026. The solicitation permits sole awards, dual awards, or multi-awards based on therapeutic considerations, product availability, patient safety, and member-specific needs, with performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. No specific set-aside designations or restrictions limiting responses to particular business classifications are disclosed in the available documentation.